You just read:

Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma

News provided by

Daiichi Sankyo

Feb 17, 2017, 06:00 ET